Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 256-005-5 | CAS number: 42928-85-8
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
No gene mutations were induced in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 when the substance was tested according to OECD 471 guideline.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 01 June 2017 - 01 August 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- 21 July 1997
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Histidine operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Details on mammalian cell type (if applicable):
- n/a
- Additional strain / cell type characteristics:
- not applicable
- Cytokinesis block (if used):
- n/a
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fraction obtained from the liver of rats treated with Aroclor 1254 (500 mg/kg) by the intraperitoneal route
- Test concentrations with justification for top dose:
- The highest recommended dose level of 5000 µg/plate was achievable. Thus, the dose levels selected for the preliminary test were 10, 100, 500, 1000, 2500 and 5000 µg/plate.
No precipitate was observed in the Petri plates when scoring the revertants at any of the tested dose levels.
Without S9 mix, a moderate to strong toxicity (decrease in the number of revertants and/or thinning of the bacterial lawn) was noted at dose levels equal or above 500 µg/plate in the TA 100 strain, equal or above 1000 µg/plate in the TA 98 strain and at 5000 µg/plate in the TA 102 strain.
With S9 mix, a moderate toxicity was noted at dose levels equal or above 2500 µg/plate in the TA 98 strain and at 5000 µg/plate in the TA 100 strain.
Therfore, the selection of the highest dose level for the main experiments was based on the level of toxicity, according to the criteria specified in the international guidelines.
Without S9 mix:
Selected dose levels were:
- 20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the TA 102 strain in the 1st experiment,
- 6.86, 20.6, 61.7, 185.2, 555.6 and 1667 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the 1st experiment,
- 31.3, 62.5, 125, 250, 500 and 1000 µg/plate for the TA 1535, TA 1537, TA 98 and TA 102 strains in the 2nd experiment,
- 15.6, 31.3, 62.5, 125, 250 and 500 µg/plate for the TA 100 strain in the 2nd experiment.
With S9 mix:
The selected dose levels were:
- 20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the 5 strains in the 1st experiment,
- 25, 50, 100, 200, 400 and 800 µg/plate for the TA 102 strain in the 2nd experiment,
- 12.5, 25, 50, 100, 200 and 400 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the 2nd experiment. - Vehicle / solvent:
- - Vehicle used: dimethylsulfoxide (DMSO).
- Justification for choice: the test item was soluble in the vehicle at 100 mg/mL. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- see Table 7.6.1/1
- Positive control substance:
- 9-aminoacridine
- 2-nitrofluorene
- sodium azide
- mitomycin C
- Remarks:
- without S9 mix
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- see Table 7.6.1/1
- Positive control substance:
- benzo(a)pyrene
- other: 2-anthramine
- Remarks:
- With S9 mix
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: direct plate incorporation method except for the second experiment with S9 mix, which was performed according to the pre-incubation method (60 minutes, 37°C).
DURATION
- Preincubation period: 60 minutes, 37°C (for 2nd experiment with S9 mix only).
- Exposure duration: 48 to 72 hours.
DETERMINATION OF CYTOTOXICITY
- Method: decrease in number of revertant colonies and/or thinning of the bacterial lawn
NUMBER OF REPLICATIONS:
Three plates/dose level. - Evaluation criteria:
- Acceptance criteria:
Each main experiment was considered valid if the following criteria are fully met:
-> the mean number of revertants in the vehicle controls is consistent with the historical data, in each strain and test condition (see table 7.6.1/2),
-> at least five analyzable dose levels (i.e. including at least three non-cytotoxic dose levels) are obtained for each strain and test condition,
-> the mean number of revertants in the positive controls is higher than that of the vehicle controls (at least 2-fold increase (for the TA 98, TA 100 and TA 102 strains) or at least 3-fold increase (for the TA 1535 and TA 1537 strains)).
When these criteria were not met for one strain or test condition, the corresponding results were invalidated and the experiment was repeated.
Criteria for assessing mutagenic potential:
In all cases, biological relevance (such as reproducibility and reference to historical data) was taken into consideration when evaluating the results.
->The test item was considered to have shown mutagenic activity in the study if:
- a reproducible 2-fold increase (for the TA 98, TA 100 and TA 102 strains) or 3-fold increase (for the TA 1535 and TA 1537 strains)
in the mean number of revertants compared with the vehicle controls was observed, in any strain, at any dose level,
- and/or a reproducible dose-response relationship was evidenced.
->The test item was considered to have shown no mutagenic activity in the study if:
- neither an increase in the mean number of revertants, reaching 2-fold (for the TA 98, TA 100 and TA 102 strains)
or 3-fold (for the TA 1535 and TA 1537 strains) the vehicle controls value, was observed at any of the tested dose levels,
- nor any evidence of a dose-response relationship was noted. - Statistics:
- no
- Key result
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Remarks:
- see tables 7.6.1/2 to 7.6.1/5
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: In the main experiment, no precipitate was observed in the Petri plates when scoring the revertants at any of the tested dose levels.
RANGE-FINDING STUDY:
- No precipitate was observed in the Petri plates when scoring the revertants at any of the tested dose levels.
- Without S9 mix, a moderate to strong toxicity (decrease in the number of revertants and/or thinning of the bacterial lawn) was noted at dose levels equal or above to 500 µg/plate in the TA 100 strain, equal or above to 1000 µg/plate in the TA 98 strain and at 5000 µg/plate in the TA 102 strain.
- With S9 mix, a moderate toxicity was noted at dose levels equal or above to 2500 µg/plate in the TA 98 strain and at 5000 µg/plate in the TA 100 strain.
COMPARISON WITH HISTORICAL CONTROL DATA: The mean revertant colony counts for the vehicle controls were within the current historical control range of the laboratory (see table 7.6.1/ 2 in Any Other Information on Materials and methods).
RESULTS OF CYTOTOXICITY and GENOTOXICITY:
Experiments without S9 mix
- A moderate to strong toxicity was noted at dose levels equal or above 250 µg/plate in the TA 1535, TA 1537, TA 98 and TA 102 strains and at dose levels equal or above 125 µg/plate in the TA 100 strain.
- Slight increases in the number of revertants were noted in the TA 1537 strain in the second experiment. Since these increases did not reach the positive threshold of 3-fold the vehicle control value, were not dose-related and since no similar results were observed in the first experiment, they were considered to be non-biologically relevant.
No other noteworthy increase in the number of revertants was observed in any other strains.
Experiments with S9 mix
- When using the direct plate incorporation method (i.e. first experiment), a moderate to strong toxicity was noted at 5000 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains. When using the pre-incubation method (i.e. second experiment), a moderate to strong toxicity was noted at dose levels equal or above 200 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains and at 800 µg/plate in the TA 102 strain. In the TA 1537 and TA 100 strains, the strong toxicity induced at 400 µg/plate prevented the scoring of revertant colonies (presence of microcolonies).
- The test item did not induce any noteworthy increase in the number of revertants, in any strains and test conditions. - Conclusions:
- The test item did not show any mutagenic activity in the bacterial reverse mutation test with Salmonella typhimurium strains, either in the presence or absence of a rat liver metabolizing system.
- Executive summary:
The objective of the study was to evaluate the potential of the test item to induce reverse mutations in Salmonella typhimurium. The study was performed according to OECD No. 471 guideline and in compliance with the principles of Good Laboratory Practice. A preliminary toxicity test was performed to define the dose levels of the test item, dissolved in dimethylsulfoxide (DMSO), to be used for the mutagenicity experiments. The test item was then tested in two independent experiments, both with and without a metabolic activation system, the S9 mix, prepared from a liver post-mitochondrial fraction (S9 fraction) of rats induced with Aroclor 1254.
Treatments were performed according to the direct plate incorporation method except for the second experiment with S9 mix, which was performed according to the pre-incubation method (60 minutes). Five strains of bacteria Salmonella typhimurium were used: TA 1535, TA 1537, TA 98, TA 100 and TA 102. Each strain was exposed to six dose levels of the test item (three plates/dose level). After 48 to 72 hours of incubation at 37°C, the revertant colonies were scored. The evaluation of the toxicity was performed on the basis of the observation of the decrease in the number of revertant colonies and/or a thinning of the bacterial lawn.
The mean number of revertants for the vehicle and positive controls met the acceptance criteria. Also, there were at least five analysable dose levels for each strain and test condition. The study was therefore considered to be valid. The selection of the highest dose level for the main experiments was based on the level of toxicity, according to the criteria specified in the international guidelines.
No precipitate was observed in the Petri plates when scoring the revertants at any of the tested dose levels.
Without S9 mix, the selected dose levels were:
- 20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the TA 102 strain in the first experiment,
- 6.86, 20.6, 61.7, 185.2, 555.6 and 1667 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the first experiment,
- 31.3, 62.5, 125, 250, 500 and 1000 µg/plate for the TA 1535, TA 1537, TA 98 and TA 102 strains in the second experiment,
- 15.6, 31.3, 62.5, 125, 250 and 500 µg/plate for the TA 100 strain in the second experiment.
A moderate to strong toxicity was noted at dose levels equal or above 250 µg/plate in the TA 1535, TA 1537, TA 98 and TA 102 strains and equal or above 125 µg/plate in the TA 100 strain. No increase in the number of revertants which could be considered as biologically relevant was observed in any tested strains.
With S9 mix, the selected dose levels were:
- 20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the five strains in the first experiment,
- 25, 50, 100, 200, 400 and 800 µg/plate for the TA 102 strain in the second experiment,
- 12.5, 25, 50, 100, 200 and 400 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the second experiment.
When using the direct plate incorporation method (i.e. first experiment), a moderate to strong toxicity was noted at 5000 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains. When using the pre-incubation method (i.e. second experiment), a moderate to strong toxicity was noted at dose levels equal or above 200 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains and at 800 µg/plate in the TA 102 strain. In the TA 1537 and TA 100 strains, the strong toxicity induced at 400 µg/plate prevented the scoring of revertant colonies.The test item did not induce any noteworthy increase in the number of revertants, in any strains and test conditions.
The test item did not show any mutagenic activity in the bacterial reverse mutation test with Salmonella typhimurium strains, either in the presence or absence of a rat liver metabolizing system.
Reference
7.6.1/2: Number of revertants per plate (mean of triplicates) in the absence of metabolic activation in the first test (direct plate incorporation method)
Strain |
Compound |
Dose-level (µg/plate) |
With or without S9 mix |
Number of revertant per plate |
Mean revertant colony count (SD) |
TA1535 |
NAN3 |
1 |
- |
537-496-546 |
526.3 (26.7) |
TEST ITEM |
1667 |
- |
7St-9St-4St |
6.7 (2.5) |
|
555.6 |
- |
7Mt-3Mt-4Mt |
4.7 (2.1) |
||
185.2 |
- |
10-8-9 |
9.0 (1.0) |
||
61.7 |
- |
6-6-10 |
7.3 (2.3) |
||
20.6 |
- |
7-4-6 |
5.7 (1.5) |
||
6.86 |
- |
8-7-10 |
8.3 (1.5) |
||
DMSO |
|
- |
12-8-9 |
9.7 (2.1) |
|
TA1537 |
9 AA |
50 |
- |
88-51-75 |
71.3 (18.8) |
TEST ITEM |
1667 |
- |
2St-2St-3St |
2.3 (0.6) |
|
555.6 |
- |
3Mt-4Mt-4Mt |
3.7 (0.6) |
||
185.2 |
- |
4-4-6 |
4.7 (1.2) |
||
61.7 |
- |
3-4-3 |
3.3 (0.6) |
||
20.6 |
- |
6-7-4 |
5.7 (1.5) |
||
6.86 |
- |
7-3-9 |
6.3 (3.1) |
||
DMSO |
|
- |
9-4-9 |
7.3 (2.9) |
|
TA 98 |
2 NF |
0.5 |
- |
107-112-86 |
101.7 (13.8) |
TEST ITEM |
1667 |
- |
11St-12St-13St |
12 (1.0) |
|
555.6 |
- |
11Mt-12Mt-10Mt |
11 (1.0) |
||
185.2 |
- |
11-19-12 |
14.0 (4.4) |
||
61.7 |
- |
13-19-15 |
15.7 (3.1) |
||
20.6 |
- |
21-18-21 |
20 (1.7) |
||
6.86 |
- |
29-11-10 |
16.7 (10.7) |
||
DMSO |
|
- |
18-10-21 |
16.3 (5.7) |
|
TA 100 |
NAN3 |
1 |
- |
484-473-433 |
463.3 (26.8) |
TEST ITEM |
1667 |
- |
60St-48St-95St |
67.7 (24.4) |
|
555.6 |
- |
76St-87St-85St |
82.7 (5.9) |
||
185.2 |
- |
79Mt-78Mt-113Mt |
90 (19.9) |
||
61.7 |
- |
85-72-70 |
75.7 (8.1) |
||
20.6 |
- |
73-77-81 |
77 (4.0) |
||
6.86 |
- |
76-79-60 |
71.7 (10.2) |
||
DMSO |
|
- |
72-102-85 |
86.3 (15.0) |
|
TA102 |
MMC |
0.5 |
- |
1869-1985-2004 |
1952.7 (73.1) |
TEST ITEM |
5000 |
- |
182St-177St-188St |
182.3 (5.5) |
|
1667 |
- |
184St-151St-149ST |
161.3 (19.7) |
||
555.6 |
- |
201St-179St-140St |
173.3 (30.9) |
||
185.2 |
- |
341-318-369 |
342.7 (25.5) |
||
61.7 |
- |
362-348-321 |
343.7 (20.8) |
||
20.6 |
- |
411-445-417 |
424.3 (18.1) |
||
DMSO |
|
- |
445-409-399 |
417.7 (24.2) |
7.6.1/3: Number of revertants per plate (mean of triplicates) in the presence of metabolic activation in the first test (direct plate incorporation method)
Strain |
Compound |
Dose-level (µg/plate) |
With or without S9 mix |
Number of revertant per plate |
Mean revertant colony count (SD) |
TA1535 |
2AM |
2 |
+ |
138 -153 -135 |
142.0 (9.6) |
TEST ITEM |
5000 |
+ |
8Mt-16Mt-11Mt |
11.7 (4.0) |
|
1667 |
+ |
6-8-11 |
8.3 (2.5) |
||
555.6 |
+ |
9-16-13 |
12.7 (3.5) |
||
185.2 |
+ |
12-6-13 |
10.3 (3.8) |
||
61.7 |
+ |
10-12-8 |
10.0 (2.0) |
||
20.6 |
+ |
4-7-8 |
6.3 (2.1) |
||
DMSO |
|
+ |
11-10-11 |
10.7 (0.6) |
|
TA1537 |
2AM |
2 |
+ |
78-87-82 |
82.3 (4.5) |
TEST ITEM |
5000 |
+ |
7Mt-4Mt-7Mt |
6.0 (1.7) |
|
1667 |
+ |
4-3-7 |
4.7 (2.1) |
||
555.6 |
+ |
10-8-9 |
9.0 (1.0) |
||
185.2 |
+ |
8-6-10 |
8.0 (2.0) |
||
61.7 |
+ |
23-6-7 |
12.0 (9.5) |
||
20.6 |
+ |
6-8-8 |
7.3 (1.2) |
||
DMSO |
|
+ |
9-8-11 |
9.3 (1.5) |
|
TA 98 |
2 AM |
2 |
+ |
817-981-888 |
895.3 (82.2) |
TEST ITEM |
5000 |
+ |
12Mt-20Mt-9Mt |
13.7 (5.7) |
|
1667 |
+ |
15-17-19 |
17 (2.0) |
||
555.6 |
+ |
21-17-22 |
20.0 (2.6) |
||
185.2 |
+ |
19-19-26 |
21.3 (4.0) |
||
61.7 |
+ |
12-21-23 |
18.7(5.9) |
||
20.6 |
+ |
19-22-25 |
22.0 (3.0) |
||
DMSO |
|
+ |
17-18-23 |
19.3 (3.2) |
|
TA 100 |
BaP |
5 |
+ |
1083-1085-1082 |
1083.3 (1.5) |
TEST ITEM |
5000 |
+ |
85St-87St-104St |
92.0 (10.4) |
|
1667 |
+ |
98-100-114 |
104.0 (8.7) |
||
555.6 |
+ |
108-104-103 |
105.0 (2.6) |
||
185.2 |
+ |
105-125-107 |
112.3 (11.0) |
||
61.7 |
+ |
102-124-108 |
111.3 (11.4) |
||
20.6 |
+ |
103-111-105 |
106.3 (4.2) |
||
DMSO |
|
+ |
113-143-98 |
118.0 (22.9) |
|
TA102 |
2AM |
20 |
+ |
2633-2639-3372 |
2881.3 (424.9) |
TEST ITEM |
5000 |
+ |
436-361-351 |
382.7 (46.5) |
|
1667 |
+ |
503-437-457 |
465.7(33.8) |
||
555.6 |
+ |
464-391-433 |
429.3 (36.6) |
||
185.2 |
+ |
448-479-423 |
450.0 (28.1) |
||
61.7 |
+ |
447-463-443 |
451.0 (10.6) |
||
20.6 |
+ |
489-504-470 |
487.7 (17.0) |
||
DMSO |
|
+ |
499-514-441 |
484.7 (38.6) |
7.6.1/4: Number of revertants per plate (mean of triplicates) in the absence of metabolic activation in the second test (direct plate incorporation method)
Strain |
Compound |
Dose-level (µg/plate) |
With or without S9 mix |
Number of revertant per plate |
Mean revertant colony count (SD) |
TA1535 |
NAN3 |
1 |
- |
636-666-690 |
664.0 (27.1) |
TEST ITEM |
1000 |
- |
15Mt-11Mt-9Mt |
11.7 (3.1) |
|
500 |
- |
9Mt-13Mt-4Mt |
8.7 (4.5) |
||
250 |
- |
8Mt-7Mt-9Mt |
8.0 (1.0) |
||
125 |
- |
13-16-2 |
10.3 (7.4) |
||
62.5 |
- |
9-6-13 |
9.3 (3.5) |
||
31.3 |
- |
11-8-11 |
10.0 (1.7) |
||
DMSO |
|
- |
4-7-15 |
8.7 (5.7) |
|
TA1537 |
9AA |
50 |
- |
210-292-287 |
263.0 (46.0) |
TEST ITEM |
1000 |
- |
4Mt-4Mt-6Mt |
4.7 (1.2) |
|
500 |
- |
8Mt-3Mt-4Mt |
5.0 (2.6) |
||
250 |
- |
9Mt-7Mt-3Mt |
6.3 (3.1) |
||
125 |
- |
3-1-9 |
4.3 (4.2) |
||
62.5 |
- |
7-3-6 |
5.3 (2.1) |
||
31.3 |
- |
9-8-6 |
7.7 (1.5) |
||
DMSO |
|
- |
2-3-3 |
2.7 (0.6) |
|
TA 98 |
2 NF |
0.5 |
- |
151-139-143 |
144.3 (6.1) |
TEST ITEM |
1000 |
- |
20Mt-12Mt-17Mt |
16.3 (4.0) |
|
500 |
- |
20Mt-15Mt-17Mt |
17.3 (2.5) |
||
250 |
- |
12Mt-17Mt-17Mt |
15.3 (2.9) |
||
125 |
- |
7-17-16 |
13.3 (5.5) |
||
62.5 |
- |
12-12-18 |
14.0 (3.5) |
||
31.3 |
- |
13-15-11 |
13.0 (2.0) |
||
DMSO |
|
- |
17-18-17 |
17.3 (0.6) |
|
TA 100 |
NAN3 |
1 |
- |
559-568-595 |
574.0 (18.7) |
TEST ITEM |
500 |
- |
100Mt-115Mt-89Mt |
101.3 (13.1) |
|
250 |
- |
79Mt-97Mt-104Mt |
93.3 (12.9) |
||
125 |
- |
93Mt-79Mt-93Mt |
88.3 (8.1) |
||
62.5 |
- |
91-78-107 |
92.0 (14.5) |
||
31.3 |
- |
88-97-105 |
96.7 (8.5) |
||
15.6 |
- |
101-77-69 |
82.3 (16.7) |
||
DMSO |
|
- |
96-83-78 |
85.7 (9.3) |
|
TA102 |
MMC |
0.5 |
- |
2462-2453-2235 |
2383.3 (128.5) |
TEST ITEM |
1000 |
- |
237St-219St-172St |
209.3 (33.6) |
|
500 |
- |
283Mt-335Mt-309Mt |
309.0 (26.0) |
||
250 |
- |
278Mt-332Mt-344Mt |
318.0 (35.2) |
||
125 |
- |
323-325-296 |
314.7 (16.2) |
||
62.5 |
- |
379-342-381 |
367.3 (22.0) |
||
31.3 |
- |
385-353-373 |
370.3 (16.2) |
||
DMSO |
|
- |
343-339-357 |
346.3 (9.5) |
7.6.1/5: Number of revertants per plate (mean of triplicates) in the presence of metabolic activation in the second test (preincubation method)
Strain |
Compound |
Dose-level (µg/plate) |
With or without S9 mix |
Number of revertant per plate |
Mean revertant colony count (SD) |
TA1535 |
2AM |
2 |
+ |
187-154-163 |
168.0 (17.1) |
TEST ITEM |
400 |
+ |
6st-13St-3St |
7.3 (5.1) |
|
200 |
+ |
12Mt-11Mt-7Mt |
10.0 (2.6) |
||
100 |
+ |
11-12-10 |
11.0 (1.0) |
||
50 |
+ |
10-10-18 |
12.7 (4.6) |
||
25 |
+ |
13-16-12 |
13.7 (2.1) |
||
12.5 |
+ |
15-13-9 |
12.3 (3.1) |
||
DMSO |
|
+ |
17-15-11 |
14.3 (3.1) |
|
TA1537 |
2AM |
2 |
+ |
63-65-70 |
66.0 (3.6) |
TEST ITEM |
400 |
+ |
StUpMc-StUpMc-StUpMc |
|
|
200 |
+ |
6St-6St-8St |
6.7 (1.2) |
||
100 |
+ |
6-7-6 |
6.3 (0.6) |
||
50 |
+ |
8-7-13 |
9.3 (3.2) |
||
25 |
+ |
17-16-12 |
15.0 (2.6) |
||
12.5 |
+ |
10-10-8 |
9.3 (1.2) |
||
DMSO |
|
+ |
12-15-7 |
11.3 (4.0) |
|
TA 98 |
2 AM |
2 |
+ |
151-139-143 |
144.3 (6.1) |
TEST ITEM |
400 |
+ |
16St-9St-10St |
11.7 (3.8) |
|
200 |
+ |
17st-29St-21St |
22.3 (6.1) |
||
100 |
+ |
25-25-27 |
25.7 (1.2) |
||
50 |
+ |
27-31-27 |
28.3 (2.3) |
||
25 |
+ |
23-38-16 |
25.7(11.2) |
||
12.5 |
+ |
26-21-23 |
23.3 (2.5) |
||
DMSO |
|
+ |
27-20-21 |
22.7 (3.8) |
|
TA 100 |
BaP |
5 |
+ |
647-858-816 |
773.7 (111.7) |
TEST ITEM |
400 |
+ |
StUpMc-StUpMc-StUpMc |
|
|
200 |
+ |
104St-93St-107St |
101.3 (7.4) |
||
100 |
+ |
129-141-124 |
131.3 (8.7) |
||
50 |
+ |
149-149-144 |
147.3 (2.9) |
||
25 |
+ |
160-130-143 |
144.3 (15.0) |
||
12.5 |
+ |
133-142-133 |
136.0 (5.2) |
||
DMSO |
|
+ |
102-119-126 |
115.7 (12.3) |
|
TA102 |
2AM |
20 |
+ |
1629-1883-1477 |
1663.0 (205.1) |
TEST ITEM |
800 |
+ |
155St-219St-176St |
183.3 (32.6) |
|
400 |
+ |
310-358-329 |
332.3 (24.2) |
||
200 |
+ |
423-378-391 |
397.3 (23.2) |
||
100 |
+ |
397-369-424 |
396.7 (27.5) |
||
50 |
+ |
461-433-377 |
423.7 (42.8) |
||
25 |
+ |
328-448-451 |
409.0 (70.2) |
||
DMSO |
|
+ |
423-388-436 |
415.7 (24.8) |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
This key study was performed according to OECD No. 471 guideline and in compliance with the principles of Good Laboratory Practice. A preliminary toxicity test was performed to define the dose levels of the test item, dissolved in dimethylsulfoxide (DMSO), to be used for the mutagenicity experiments. The test item was then tested in two independent experiments, both with and without a metabolic activation system, the S9 mix, prepared from a liver post-mitochondrial fraction (S9 fraction) of rats induced with Aroclor 1254.
Treatments were performed according to the direct plate incorporation method except for the second experiment with S9 mix, which was performed according to the pre-incubation method (60 minutes). Five strains of bacteria Salmonella typhimurium were used: TA 1535, TA 1537, TA 98, TA 100 and TA 102. Each strain was exposed to six dose levels of the test item (three plates/dose level). After 48 to 72 hours of incubation at 37°C, the revertant colonies were scored. The evaluation of the toxicity was performed on the basis of the observation of the decrease in the number of revertant colonies and/or a thinning of the bacterial lawn.
The mean number of revertants for the vehicle and positive controls met the acceptance criteria. Also, there were at least five analysable dose levels for each strain and test condition. The study was therefore considered to be valid. The selection of the highest dose level for the main experiments was based on the level of toxicity, according to the criteria specified in the international guidelines.
No precipitate was observed in the Petri plates when scoring the revertants at any of the tested dose levels.
Without S9 mix, the selected dose levels were:
-20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the TA 102 strain in the first experiment,
- 6.86, 20.6, 61.7, 185.2, 555.6 and 1667 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the first experiment,
- 31.3, 62.5, 125, 250, 500 and 1000 µg/plate for the TA 1535, TA 1537, TA 98 and TA 102 strains in the second experiment,
- 15.6, 31.3, 62.5, 125, 250 and 500 µg/plate for the TA 100 strain in the second experiment.
A moderate to strong toxicity was noted at dose levels equal or above 250 µg/plate in the TA 1535, TA 1537, TA 98 and TA 102 strains and equal or above 125 µg/plate in the TA 100 strain. No increase in the number of revertants which could be considered as biologically relevant was observed in any tested strains.
With S9 mix, the selected dose levels were:
- 20.6, 61.7, 185.2, 555.6, 1667 and 5000 µg/plate for the five strains in the first experiment,
- 25, 50, 100, 200, 400 and 800 µg/plate for the TA 102 strain in the second experiment,
- 12.5, 25, 50, 100, 200 and 400 µg/plate for the TA 1535, TA 1537, TA 98 and TA 100 strains in the second experiment.
When using the direct plate incorporation method (i.e.first experiment), a moderate to strong toxicity was noted at 5000 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains. When using the pre-incubation method (i.e.second experiment), a moderate to strong toxicity was noted at dose levels equal or above 200 µg/plate in the TA 1535, TA 1537, TA 98 and TA 100 strains and at 800 µg/plate in the TA 102 strain. In the TA 1537 and TA 100 strains, the strong toxicity induced at 400 µg/plate prevented the scoring of revertant colonies.The test item did not induce any noteworthy increase in the number of revertants, in any strains and test conditions.
The test item did not show any mutagenic activity in the bacterial reverse mutation test with Salmonella typhimurium strains, either in the presence or absence of a rat liver metabolizing system.
Justification for classification or non-classification
The substance is not mutagenic in bacteria.
However, further testing should be performed to definitely classify the substance regarding its genetic toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
